Strategic Partnerships Rakuten Medical has attracted investment from LOTTE Holdings and formed a manufacturing partnership with LOTTE Biologics, indicating strong interest from large corporate investors and potential for co-development or supply chain collaborations.

Executive Leadership Transition A planned leadership change with a new CEO taking the helm on July 1, 2026, presents an opportunity to engage for strategic alliances, joint funding rounds, and renewed market expansion plans.

Global Expansion With offices across the United States, Japan, Taiwan, Switzerland and India, and ongoing clinical and preclinical activities, there is a broad geographic footprint favorable for multi-region partnerships and regional manufacturing or regulatory support.

Clinical Momentum Recent ASCO and AACR activities plus preclinical findings around COX-2 inhibition suggest active clinical development and interest in partnerships for trials, co-authored publications, or financing to accelerate go‑to‑market timelines.

Scale and Capabilities Significant funding and a high revenue range, plus a dedicated Alluminox platform, indicate readiness for strategic deals in manufacturing, distribution, or licensing of photoimmunotherapy technologies to expand treatment modalities and geographic reach.